Varma Mutual Pension Insurance Co Acquires Shares of 337,981 Boston Scientific Corporation $BSX

Varma Mutual Pension Insurance Co acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 337,981 shares of the medical equipment provider’s stock, valued at approximately $14,425,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Westpac Banking Corp bought a new position in Boston Scientific during the second quarter worth about $978,000. TRB Wealth Management LLC acquired a new stake in Boston Scientific in the 2nd quarter worth about $247,000. Sumitomo Life Insurance Co. bought a new stake in Boston Scientific in the 2nd quarter valued at about $7,569,000. William Blair Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $1,979,000. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $4,169,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a report on Friday, June 12th. BTIG Research cut their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, July 29th. Truist Financial reduced their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Oppenheimer lowered their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 27th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Boston Scientific Price Performance

Shares of BSX stock opened at $50.39 on Monday. The business has a fifty day simple moving average of $46.34 and a 200 day simple moving average of $57.62. The company has a market cap of $73.03 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.